Director/PDMR Shareholding - Replacement

RNS Number : 3416V

GlaxoSmithKline PLC

10 January 2012

 



This announcement replaces the original announcement released on 3 January 2012 at 17.30 (RNS No: 9377U).

Due to an administrative error the change in one of the Non-Executive Director's interests in the American Depositary Shares (ADSs) of GlaxoSmithKline plc indicated with an asterisk (*) below, was incorrectly stated in the announcement made on 3 January 2012.

Save as disclosed above, all other details remain unchanged. The full amended text is shown below.

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the directors' interests in the Ordinary shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc.

On 30 December 2011, the Company's Non-Executive Directors were provisionally allocated the following awards over Ordinary shares and American Depositary Shares (ADSs) in the Company through the annual reinvestment of dividends paid throughout 2011:

GlaxoSmithKline Non-Executive Directors Automatic Share Award and Elected Share Award- Annual Dividend Reinvestment

Non-Executive Director	No. of Ordinary Shares	Average Price (£)	No. of ADSs	Average Price ($)
Sir Christopher Gent	3,072.732	14.70
Prof Sir Roy Anderson	408.069	14.70
Dr Stephanie Burns			361.105	45.53
Ms Stacey Cartwright	3.865	14.70
Mr Lawrence Culp			1,133.685	45.53
Sir Crispin Davis	2,536.065	14.70
Ms Judy Lewent			1.998*	45.53
Sir Deryck Maughan			1,033.536	45.53
Mr James Murdoch	474.157	14.70
Dr Daniel Podolsky			623.023	45.53
Mr Tom de Swaan	612.754	14.70
Sir Robert Wilson	710.997	14.70

The Company and the Non-Executive Directors were informed of these allocations on

3 January 2012.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte

Company Secretary

10 January 2012

 

END

 

 

RDSEAPFEFAFAEFF